1,881 cases and 5 deaths in the last 24 hours / Argentina News

Other 5 people died and 1,881 New cases of coronavirus were repounded in the last 24 hours in Argentina, bringing the total to 116,703 deaths officially registered at the national level and 5,348,123 those infected since the start of the pandemic, the Ministry of Health reported.

Currently, there are 692 people admitted to intensive care throughout the country. Thus, the occupation of these services at the national level is 35.3% and 40.1% in the AMBA.

The tests

The Ministry also indicated that they were carried out in the last 24 hours 34,078 tests and since the beginning of the outbreak there have been 26,536,077 diagnostic tests for this disease.

Pfizer and BioNTech could have an Omicron variant vaccine ready in March 2022

Pharmaceutical companies Pfizer and BioNTech advance that their Covid-19 vaccine neutralizes the omicron variant of SARS-CoV-2 by administering three doses, the companies with preliminary data reported on Wednesday.

These two manufacturers trust that, if necessary, can deliver a specific vaccine for this variant of the coronavirus in March 2022. Anyway, so far there are no conclusive data on the aggressiveness of this new mutation and if this modification will be necessary.

The studies of these companies obtained from those vaccinated one month after receiving the booster vaccine (third dose of Comirnaty vaccine) show that this product neutralizes the omicron variant to levels that are comparable to two doses in conventional SARS-CoV-2 . Likewise, the evaluation indicates that with only two doses, the response is significantly lower than against the original SARS-CoV-2 virus.

“Although two doses of the vaccine may offer protection against severe disease caused by the Ómicron strain, it is clear from these preliminary data that protection is improved with a third dose of our vaccine,” said Albert Bourla, President and CEO of Pfizer, in a statement.

Albert Bourla, CEO of Pfizer

“Our first preliminary data set indicates that a third dose could still offer a sufficient level of protection against diseases of any severity caused by the omicron variant,” insisted Ugur Sahin, CEO and co-founder of BioNTech.

While these results are preliminary, Companies will continue to collect more laboratory data and evaluate effectiveness in the real world to assess and confirm protection against the variant and inform the most effective way forward.

It is worth mentioning that on November 25, companies began to develop a specific vaccine for the Omicron variant. As planned, development will continue in the event that a vaccine adaptation. The first batches can be produced and ready for shipment in 100 days, pending regulatory approval.

The companies have also previously started clinical trials with variant-specific vaccines (Alpha, Beta, Delta, and Alpha / Delta Mix). Pfizer and BioNTech expect to produce 4 billion doses of Comirnaty in 2022, their vaccine based on messenger RNA technology.